Margaret Bolce Brivanlou

Jan 22, 2025 | ballardspahr.com | Margaret Bolce Brivanlou |Peter A. Jaslow |Philip Legendy |Scott D. Marty

Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground in sunny San Francisco for the 43rd Annual J.P. Morgan Health Care Conference (#JPM25) January 12-15. The weather was vibrant and so was the atmosphere, with ample opportunity for networking and collaboration among prominent participants. KEY TAKEAWAYS: Cautious Optimism for Deal Making.

May 22, 2023 | ballardspahr.com | Caryn Borg-Breen |Scott D. Marty |Margaret Bolce Brivanlou |Kenneth H. Sonnenfeld

Summary In Amgen v. Sanofi, the Supreme Court unanimously affirmed the District of Delaware and Federal Circuit findings that Amgen’s functionally defined patent claims to a class of therapeutic antibodies are invalid as lacking enablement in the specification. The decision has implications for procurement and enforcement of patents to biotechnology inventions.